|

64Cu-SAR-bisPSMA Clinical Trials

3 actively recruiting trials across 2 locations

▼ -1 trial since May 2026

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Clarity Pharmaceuticals Ltd2
  • St Vincent's Hospital, Sydney1

Indications

  • Cancer3
  • Prostatic Neoplasms, Castration-Resistant1
  • Prostate Cancer (Post Prostatectomy)1
  • Prostatic Neoplasms1
  • Prostate Cancer1

Other1 trial

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Phase 2

Birmingham, Alabama1 trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

University of Alabama Birmingham Hospital

Phase 3

Stanford, California1 trial

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Stanford Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.